Navigation Links
Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announced that an interim report regarding the clinical study of BF-200 ALA in actinic keratosis was received today from an independent review committee. The objectives of the study are to investigate the efficacy and safety of several doses of BF-200 ALA in photodynamic therapy. The comments received today refer to the clinical results eight weeks after treatment. An additional report about the results after twelve weeks will follow.

The interim committee reported that no side effect justifying concerns about the safety of this dose were observed in any dose group. On the basis of the available data, the therapy was found to be safe for all doses tested.

In spite of the limited patient number, different doses gave rise to clear differences in efficacy. However, the results of the different doses were not yet disclosed. The committee announced this disclosure once it has received and analyzed the clinical results 12 weeks after treatment. Biofrontera expects this second report within few weeks.

To optimize the statistical study design, the committee has proposed to continue the phase III part of the study separately. This will enable the complete analysis of the 12-week data. On this basis, Biofrontera intends to continue the further development of the 10 % dose, provided this dose selection is supported by the 12-week data.

Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Germany ISIN: DE0006046113 WKN: 604611

Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 222 Fax.: +49 (0214) 87 63 290 e-mail: a.zurmuehlen@biofrontera.com


'"/>




Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: hoc Interim report about clinical trial ALA actinic keratosis
(Date:8/18/2008)...- Oramed,Pharmaceuticals, I...developer,of oral delivery systems, announced toda... Assess the Safety, Pharmacokinetics (PK) and,Phar...s in Healthy,Subjects," has been chosen for presen...European Association for the Study of Diabetes (EA...
(Date:8/17/2008)...nhua-- Pharmaxis,(ASX: PXS;...tal Phase 3,clinical trial of Bronchitol for the t...t., The first efficacy data from the trial is exp...9. The trial commenced its dosing phase in,April 2... subjects in June,2008 and closed today with 325 s...
(Date:8/14/2008)...BiTE) showing clinical benefit in cancer,patients;...gnize and attack canc...tCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a bioph...,antibodies for the treatment of cancer, inflammat...cation of a Phase 1 clinical study(1) on its,BiTE(...
(Date:8/13/2008)...irstCall/ -- As biotechnology,pharmaceutical and ...l,trials beyond their own borders to other parts o...h America, complicated regulatory environments,cha...ing to an analysis by,Aon Corporation (NYSE: AOC ...ose companies a visual representation of the compl...
Breaking Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Healthcare M 26A Activity on the Rise 9649 1Healthcare M 26A Activity on the Rise 9649 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 1Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 3New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 1New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 2Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 1Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 2
...ch 12, 2007: Progen Industries Limited,(ASX: PGL; ...8,Phase II liver cancer data has been accepted for...ssociation for the Study of the Liver,(EASL). Prog...er,cancer trial at the American Association for Ca...xpectation of having final data fully analysed and...
...d Safety Profile and Excellent,Pharmacokinetic Pro... 2007 /PRNewswire/ --,CeNeRx BioPharma, Inc., a cl...g innovative treatments for diseases of the centra... from a Phase I,clinical trial of Tyrima(TM), its ... anxiety. In this study, Tyrima was safe and well,...
Other Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:8/20/2008)... CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ -- ...reported preliminary income from,continuing operat... $27.5,million, or $0.76 per diluted share, includ...r diluted share, related to provisions for store,c...a 6.8 percent increase,compared with income from c...
(Date:8/20/2008)...IELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Chan...lness Promotion will give thousands of,Detroit met...LTHY LIVING,FOR KIDS" program. This year the progr...m. to 5 p.m. at the Charles H. Wright Museum of Af...7, "Healthy Living for Kids",has provided free imm...
(Date:8/20/2008)...N and OTTAWA, Aug. 20 /PRNewswire-FirstCall/ -- iN...nd information portal, announced,today the third w...g a free,Nintendo Wii and Wii Fit system. The Winn...n, Michigan. iNutrition sweepstakes winner Ron Mil...excited." He then told his,son who responded with,...
(Date:8/20/2008)...PRINGS, Pa., Aug. 20 /PRNewswire-USNewswire/ -- Go... agricultural industry is struggling,with high fue...ng the need,to secure the state,s energy independe...g adults., Nearly 900 guests gathered to hear the...ay Luncheon at Ag Progress Days, Pennsylvania,s,la...
Breaking Medicine News(10 mins):Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Weight Loss and Fitness Information Site iNutrition.com Gives Away Third Nintendo Wii and Wii Fit 2Health News:Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days 2
...lips who was on his way to becoming a lawyer says ...// “The top step had ice, and I went straight over...urs, and when they found me, I had blood coming ou... recollection for two and a half years after that ...
... their risk of birth defects. Now, new research sh...e.// Researchers say about 31,000 stroke-related d...s may have been prevented each year since fortific...s homocysteine levels. People with higher homocyst...
...esearchers say the estrogen pills do not reduce th...ed risk of stroke.// Researchers say their result...or decrease the risk of heart disease as combinati...trogen also does not appear to affect a woman’s ri...
...could help fight another. Researchers say the litt...G , may hold a key to helping researchers devise n...results from the Multicenter Acquired Immunodefici...estigators followed a large group of HIV-infected ...
Other Medicine News:
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: